CNM-Au8
Amyotrophic Lateral Sclerosis (ALS)
Key Facts
About Clene
Clene is a clinical-stage biotech leveraging its proprietary Clean-Surface Nanocrystal (CSN™) platform to develop catalytic nanotherapeutics for neurodegenerative diseases. Its lead candidate, CNM-Au8, is in advanced Phase 2/3 trials for ALS and Phase 2 for MS, targeting impaired neuronal energy metabolism. The company's strategy is to validate a disease-agnostic mechanism—enhancing cellular ATP production—across multiple indications. Having transitioned to a public entity (NASDAQ: CLNN), Clene has raised over $150 million to fund its ambitious clinical pipeline.
View full company profileAbout Clene
Clene is a clinical-stage biotech leveraging its proprietary Clean-Surface Nanocrystal (CSN™) platform to develop catalytic nanotherapeutics for neurodegenerative diseases. Its lead candidate, CNM-Au8, is in advanced Phase 2/3 trials for ALS and Phase 2 for MS, targeting impaired neuronal energy metabolism. The company's strategy is to validate a disease-agnostic mechanism—enhancing cellular ATP production—across multiple indications. Having transitioned to a public entity (NASDAQ: CLNN), Clene has raised over $150 million to fund its ambitious clinical pipeline.
View full company profileAbout Clene
Clene is a clinical-stage biotech leveraging its proprietary Clean-Surface Nanocrystal (CSN™) platform to develop catalytic nanotherapeutics for neurodegenerative diseases. Its lead candidate, CNM-Au8, is in advanced Phase 2/3 trials for ALS and Phase 2 for MS, targeting impaired neuronal energy metabolism. The company's strategy is to validate a disease-agnostic mechanism—enhancing cellular ATP production—across multiple indications. Having transitioned to a public entity (NASDAQ: CLNN), Clene has raised over $150 million to fund its ambitious clinical pipeline.
View full company profileAbout Clene
Clene is a clinical-stage biotech leveraging its proprietary Clean-Surface Nanocrystal (CSN™) platform to develop catalytic nanotherapeutics for neurodegenerative diseases. Its lead candidate, CNM-Au8, is in advanced Phase 2/3 trials for ALS and Phase 2 for MS, targeting impaired neuronal energy metabolism. The company's strategy is to validate a disease-agnostic mechanism—enhancing cellular ATP production—across multiple indications. Having transitioned to a public entity (NASDAQ: CLNN), Clene has raised over $150 million to fund its ambitious clinical pipeline.
View full company profileTherapeutic Areas
Other Amyotrophic Lateral Sclerosis (ALS) Drugs
| Drug | Company | Phase |
|---|---|---|
| NPT520-34 | Neuropore Therapies | Pre-clinical/Phase 1 |
| NUZ-001 | Neurizon Therapeutics | Phase 2/3 (Platform Trial) |
| Masitinib | AB Science | Phase 3 |
| Undisclosed Program | Zhimeng Biopharma | Clinical |
| SLS-005 | Seelos Therapeutics | Platform Trial |
| PMN442 | ProMIS Neurosciences | Preclinical |
| nAV-101 | nVector | Pre-clinical |
| ALTA-808 | Alteron Therapeutics | Preclinical |
| GM6 | Genervon Biopharmaceuticals | Phase 2 |
| Lou Gehrig’s disease | Genclis | Discovery |
| Treg-directed therapy for ALS | Iltoo Pharma | Pre-clinical |
| NG CELL | NeuroGenesis Bio | Phase 2 |